Non-Abbott product
Device
Abbott Laboratories
Total Payments
$2.9M
Transactions
17
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $2.9M | 17 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.9M | 17 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Evaluation of Cardiovascular Biomakers in the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER TIMI 59) | Abbott Laboratories | $1.5M | 0 |
| Evaluation of Cardiovascular Biomakers in the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER TIMI 59) Clinical Study - TIMI Study Group | Abbott Laboratories | $1.3M | 0 |
| Evaluation of Cardiovascular Biomarkers in the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER TIMI 59) Clinical Study TIMI Study Group | Abbott Laboratories | $60,000 | 0 |
| A Randomized Phase III Study of Ibrutinib plus obinutuzumab versus ibrutinib plus venetoclax and obinutuzumab in untreated older parents (<=70 years of age) with chronic lymphocytic leukemia (CLL) | Abbott Laboratories | $35,395 | 0 |
| Pre Determine Biologic Markers and MRI SCD Cohort Study | Abbott Laboratories | $20,000 | 0 |
| Farming for Life - Health Impact of Organic Vegetable Prescriptions for Adults Living With or at Risk of Type 2 Diabetes (FFL) | Abbott Laboratories | $1,460 | 0 |
Top Doctors Receiving Payments for Non-Abbott product
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Boston, MA | $2.9M | 17 |
Ad
Manufacturing Companies
- Abbott Laboratories $2.9M
Product Information
- Type Device
- Total Payments $2.9M
- Total Doctors 0
- Transactions 17
About Non-Abbott product
Non-Abbott product is a device associated with $2.9M in payments to 0 healthcare providers, recorded across 17 transactions in the CMS Open Payments database. The primary manufacturer is Abbott Laboratories.
Payment data is available from 2019 to 2019. In 2019, $2.9M was paid across 17 transactions to 0 doctors.
The most common payment nature for Non-Abbott product is "Unspecified" ($2.9M, 100.0% of total).
Non-Abbott product is associated with 6 research studies, including "Evaluation of Cardiovascular Biomakers in the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER TIMI 59)" ($1.5M).